GW Pharmaceuticals’ Epidyolex Approved in Australia for Severe Forms of Epilepsy
The Australian Therapeutic Goods Administration (TGA) has approved GW Pharmaceuticals’ Epidyolex (cannabidiol) to treat seizures associated with two epilepsy disorders, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.
The TGA approval is the third for Epidyolex, which the FDA approved in 2018 and the European Medicines Agency approved in 2019. It is the first cannabis-based medicine approved for use in the U.S. and Europe.
UK-based GW Pharmaceuticals has entered into an agreement with Chiesi Australia to make the medicine commercially available in Australia.